JERSEY CITY, N.J., Nov. 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced that the Company will present at the
following upcoming investor conferences:
- The 30th Annual Piper Jaffray Healthcare Conference
at the Lotte New York Palace Hotel on Tuesday, November 27, 2018 at 10:10 a.m. ET.
- The Evercore ISI HealthConX Conference at the Boston Harbor
Hotel on Wednesday, November 28, 2018
at 11:45 a.m. ET.
Live webcasts of the presentations will be available on the
Investors section of the Company's website: www.scynexis.com.
Replays of the presentations will be available approximately two
hours after each event and will be available for two weeks
following each presentation.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ:SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative therapies. The
SCYNEXIS team has extensive experience in the life sciences
industry, discovering and developing more than 30 innovative
medicines over a broad range of therapeutic areas. SCYNEXIS's lead
product candidate, ibrexafungerp (formerly SCY-078), is a novel
oral/IV antifungal agent in Phase 2 clinical and pre-clinical
development for the treatment of multiple serious and
life-threatening invasive fungal infections caused by
Candida and Aspergillus species. For more
information, visit www.scynexis.com.
CONTACT:
Investor Relations
Natalie
Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com
Media Relations
George E.
MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-inc-to-present-at-upcoming-investor-conferences-300753206.html
SOURCE SCYNEXIS, Inc.